A Comparison of Adding Exenatide with Switching to Exenatide in Patients with Type 2 Diabetes Experiencing Inadequate Glycemic Control with Sitagliptin plus Metformin

Study identifier:H8O-CR-GWDK

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Comparison of Adding Exenatide with Switching to Exenatide in Patients with Type 2 Diabetes Experiencing Inadequate Glycemic Control with Sitagliptin plus Metformin

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 4

Healthy volunteers

No

Study drug

exenatide and sitagliptin, exenatide and placebo

Sex

All

Actual Enrollment

255

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Mar 2009
Primary Completion Date: 01 Apr 2010
Study Completion Date: 01 Apr 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria